INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA

Core Viewpoint - A class action lawsuit has been filed against Iovance Biotherapeutics, Inc. concerning allegations of securities fraud and unlawful business practices [2][4]. Financial Performance - Iovance reported a total product revenue of $49.3 million for Q1 2025, down from $73.7 million in the previous quarter, indicating a significant decline [4]. - The company revised its full fiscal year 2025 total product revenue guidance from a range of $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [4]. - The updated revenue forecast reflects recent launch dynamics affecting Amtagvi, the company's lead product candidate, and considers growth trajectories and treatment timelines for new authorized treatment centers (ATCs) [4]. Stock Market Reaction - Following the financial results announcement, Iovance's stock price fell by $1.42 per share, or 44.79%, closing at $1.75 per share on May 9, 2025 [4].